Full-Time

Medicinal Chemist

Inductive Bio

Inductive Bio

11-50 employees

ML-driven software for small molecule ADMET

Compensation Overview

$210k - $250k/yr

Boston, MA, USA + 2 more

More locations: San Francisco, CA, USA | New York, NY, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Lead Generation
Machine Learning
Medicinal Chemistry
Requirements
  • An ideal candidate is a creative and accomplished medicinal chemist with a synthetic organic chemistry background who has played a meaningful role in advancing compounds to the development candidate stage.
  • You have direct experience at all stages of drug discovery projects, and can point to go/no go judgement calls you’ve made in lead generation and lead optimization.
  • You’ve used different approaches to evaluate compound quality, from LLE to dose prediction, and appreciate the importance of contextualizing results in terms of their expected profile in humans.
  • The more modalities you’ve worked with, the better, from reversible and covalent to heterobifunctionals and peptides.
  • Along with designing compounds and analyzing data, you have years of experience in chemical synthesis with CROs. As you think about synthetic strategy, you look for convergent routes and late-stage intermediates.
  • You communicate effectively and proactively, seek feedback, handle proprietary information with discretion, embrace transparency, and treat others with respect.
Responsibilities
  • Be an embedded expert, supporting a variety of partner drug discovery programs from lead generation through development candidate nomination across diverse small molecule modalities.
  • Alongside outstanding compchem, DMPK, and machine learning colleagues, bring Inductive’s tools and your medchem knowledge to our work as consultants on partners’ projects.
  • Help deliver value to partners through Inductive’s experimental offerings, where we combine our drug discovery experience, predictive models, and AI workflows with our chemistry and assay CRO partners to answer hypotheses effectively.
  • Build an AI-native drug discovery platform that will speed drugs to the clinic. Help make your ideas about how to improve the DMTA cycle a reality, as we flesh out Indy (our AI medicinal chemistry agent) and build assay and synthesis workflows that get to high-quality answers more quickly.
  • Represent Inductive’s mission and build connections in the field, meeting with current and potential partners, gathering feedback about what drug discovery teams need, attending conferences and meetings, giving presentations, and authoring blog posts and publications.
Desired Qualifications
  • Experience with predictive models and automation is a plus! (e.g. FEP, predictive ADME, AI retrosynthesis, direct to biology)

Inductive Bio uses machine learning on a proprietary, curated dataset to help pharmaceutical, biotech, and research teams design small molecule drugs. Its platform provides real-time ADMET predictions and data-driven insights to guide drug design throughout development. The system stands out by pairing a thoroughly curated ADMET dataset with ML models in a user-friendly platform that supports entire teams, not just data scientists. The goal is to accelerate the discovery and optimization of safe, effective small molecule drugs by delivering practical, data-driven guidance during development.

Company Size

11-50

Company Stage

Series A

Total Funding

$29.3M

Headquarters

San Francisco, California

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • $25M Series A from Obvious Ventures on May 7, 2025, expands Compass and data consortium.
  • DATAMAP secures $21M to build AI toxicity models with Amgen and FDA validation.
  • Nested Therapeutics collaboration published July 29, 2024, reduced synthesized compounds.

What critics are saying

  • Schrödinger's LiveDesign outperforms Beacon models, eroding subscriptions in 6-12 months.
  • Exscientia's end-to-end platform with 8 clinical assets commoditizes ADMET niche in 12-18 months.
  • Polaris Therapeutics open-sources ADMET models, slashing Compass demand in 3-6 months.

What makes Inductive Bio unique

  • Beacon-1 models won OpenADMET-ExpansionRx on Feb 3, 2026, topping 370 submissions.
  • Compass platform delivers real-time ADMET predictions, accelerating compound optimization.
  • Proprietary datasets power ML models guiding dozens of biopharma programs to candidates.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Inductive Bio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Commuter Benefits

Phone/Internet Stipend

Home Office Stipend

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Unlimited Paid Time Off

401(k) Retirement Plan

401(k) Company Match

Company Equity

Stock Options

Wellness Program

Mental Health Support

Professional Development Budget

Conference Attendance Budget

Tuition Reimbursement

Professional Certification Support

Training Programs

Pet Insurance

Adoption Assistance

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Relocation Assistance

Employee Discounts

Meal Benefits

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

3%

2 year growth

-3%
Inductive Bio
Dec 9th, 2025
Inductive Bio Announces an up to $21M Award to Develop AI Drug Toxicity Models

Team to develop and validate computational models trained on data from organoids and advanced human model systems that will improve drug safety and reduce reliance on animal testing

Third News
Dec 8th, 2025
Inductive Bio secures $21M to develop AI drug toxicity models reducing animal testing

Inductive Bio has secured up to $21 million in funding to develop AI-driven drug toxicity models that could transform safety assessments in drug discovery. The initiative, called DATAMAP, involves collaboration with Amgen, Cincinnati Children's Hospital Medical Center, Baylor College of Medicine and Torch Bio. The project aims to reduce reliance on animal testing by using human-derived data from organoid systems to predict drug safety more accurately. Currently, nearly 90% of clinical-stage drug candidates fail to reach market, with 25% failing due to unforeseen safety issues. The initial phase will focus on drug-induced liver injury and cardiotoxicity, which account for over 40% of drug withdrawals. Inductive Bio will work with the FDA to validate these AI models for regulatory approval, aligning with the agency's push to modernise drug development methodologies.

AlleyWatch
May 16th, 2025
Inductive Bio Raises $25M for AI Drug Discovery

Inductive Bio has secured $25M in Series A funding led by Obvious Ventures, with participation from a16z Bio + Health, Lux Capital, and others. The company aims to transform drug discovery with its collaborative AI platform, which accelerates compound optimization by predicting molecular behavior before lab synthesis. This approach reduces costs and speeds up drug development. Inductive Bio's platform has shown success in the Polaris ADMET competition and plans to expand its team and platform reach.

FinSMEs
May 7th, 2025
Inductive Bio Raises $25M in Series A Funding

Inductive Bio raises $25M in Series A funding.

BiopharmaTrend
May 7th, 2025
Inductive Bio Raises $25M to Scale AI Platform for Predicting Drug Behavior Before Synthesis

Inductive Bio has secured $25 million in Series A financing to expand its machine learning platform for small molecule drug discovery.